Nucleai

Nucleai is an AI-driven spatial biomarker company that leverages military intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions within patient biopsies. By translating these interactions into actionable insights, Nucleai accelerates the development of life-saving treatments and diagnostics, powering the next generation of precision therapeutics.

The company serves leading biopharma organizations, research institutions, and clinical trial programs, partnering with top-tier academic and industry collaborators to unite multimodal AI technology with spatial biology. Nucleai's platform is notably the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program, with partnerships spanning more than 12 of the top 20 biopharma companies and over 25 clinical trial studies, including prospective trial enrollment.

Core Solutions and Services

• Biomarker Discovery and Validation: Identifying and validating novel spatial biomarkers to support drug development pipelines.
• Biomarker Scoring: Optimizing the quantification and scoring of biomarkers from tissue samples to support clinical decision-making.
• Genomic Biomarker Screening: Integrating genomic data to screen for relevant biomarkers across patient populations.
• Mechanism of Action (MoA): Determining how therapies interact with the tumor microenvironment and surrounding cellular architecture.
• Data Enrichment: Enhancing existing datasets with spatial and multimodal AI-derived insights to improve analytical depth.
• Companion Diagnostics: Translating spatial biology discoveries into real-world diagnostic solutions that can be deployed in clinical practice.

AI Technology and Platform Capabilities

• Nucleai's platform offers a first-of-its-kind multimodal spatial biomarker analysis solution, ingesting images from multiple modalities including H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics.
• Advanced spatial AI methods are applied to analyze complex cellular interactions within patient biopsies, generating dynamic AI-guided spatial maps of tissue architecture.
• The platform delivers actionable insights that optimize biomarker scoring, determine biomarker prevalence, elucidate mechanism of action, and predict patient response to therapy.
• The technology is designed to support the full drug development continuum, from early translational research through to companion diagnostics and clinical deployment.
• Nucleai's approach is grounded in the belief that every patient's biology is complex and unique, and that AI-guided spatial mapping of biopsies can lead to better, more personalized treatment decisions.

Partnerships, Investors, and Collaborators

• Nucleai has established partnerships with leading research institutions, including the University of Glasgow, where collaboration is focused on accelerating the translation of spatial biology insights into clinical practice to improve patient care.
• The company is backed by strategic investors including M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany.
• Nucleai works with a broad network of data and institutional partners to support its research and commercialization efforts.
• The company brings together multidisciplinary expertise spanning pathology, medicine, biology, engineering, and artificial intelligence to address complex challenges in healthcare.

Nucleai is committed to transforming patient care by revolutionizing precision medicine through AI-driven spatial biomarkers, bridging the gap between cutting-edge spatial biology research and real-world clinical diagnostics.